April 5, 2017 / 8:42 AM / 3 years ago

Boehringer eyes marked sales gain, boosted by animal health

INGELHEIM, Germany (Reuters) - Boehringer Ingelheim, Germany’s second-largest drugmaker, said on Wednesday it was targeting a marked gain in 2017 revenues, boosted by new animal health businesses it acquired from Sanofi (SASY.PA).

Unlisted Boehringer on Jan. 1 wrapped up an asset swap that saw Boehringer take Sanofi’s $13.5 billion (10.82 billion pounds) animal care subsidiary, making it Europe’s largest player in the industry.

In return, Sanofi obtained the German company’s consumer health care business unit, valued at nearly $8 billion, plus a $5.5 billion cash payment from Boehringer.

Boehringer, which invented mass production of baking powder in the 1890s and which collaborates on diabetes drugs with Eli Lilly (LLY.N), posted a 7.1 percent gain in sales to 15.9 billion euros (13.62 billion pounds) last year.

Operating income jumped 27 percent to 2.9 billion euros, helped by an upfront payment of almost $600 million from U.S. drugmaker AbbVie (ABBV.N) for the marketing rights to a promising experimental psoriasis treatment.

Reporting by Patricia Weiss; Writing by Ludwig Burger; Editing by Maria Sheahan

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below